COMP <GO>
TMDX vs JNJ // ENTERPRISE SCALE & MARKET CAP
TransMedics Group Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: TMDX 5
— JNJ 6
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $67.12 (+0.33%) • MKT CAP: $2.33B
market-cap
$2.33B
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
market-cap
$662.49B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMDX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.90% | 67.90% | -8.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.10% | 25.50% | -7.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.6x | 18.5x | -3.90 | TMDX | /valuation <GO> |
| Free Cash Flow Yield | 5.74% | 2.97% | +2.77 | TMDX | /fcf-yield <GO> |
| Operating Margin | 17.90% | 34.70% | -16.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 31.40% | 28.50% | +2.90 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) | 37.10% | 6.00% | +31.10 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.50 | 5.59 | -2.09 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.5 | 62.1 | -29.60 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.2x | 23.0x | -12.80 | TMDX | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.33B | $662.49B | -$660.16B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMDX REV | JNJ REV | TMDX GROSS % | JNJ GROSS % | TMDX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $605.5M | $94.19B | 59.9% | 67.9% | $133.6M | $19.70B |
| FY 2024 | $441.5M | $88.82B | 59.4% | 69.1% | -$80.9M | $19.84B |
| FY 2023 | $241.6M | $85.16B | — | — | -$13.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
JNJ // BETA 1.08